Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00206232 · ClinicalTrials.gov registry record · Phase 4
Novel Treatment for Diastolic Heart Failure in Women
A Phase 4 study, sponsored by Baylor College of Medicine.
- Completed
- Registry status
- Phase 4
- Development phase
- 48
- Enrollment target
NCT00206232 is a Phase 4 study that has completed, run by Baylor College of Medicine. The registered enrollment target is 48 participants.
The verdict
NCT00206232, a Phase 4 study, has completed, sponsored by Baylor College of Medicine.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 48 participants
- Enrollment target
Study Summary
The purpose of the study is to collect information about the potential benefit and safety of low dose spironolactone for a patient with diastolic heart failure (DHF) and to determine whether spironolactone can cause the patient's condition to improve.
Interventions
- DRUG Spironolactone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2004-07 |
| Est. Completion | 2010-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00206232
The ClinicalTrials.gov registry entry for NCT00206232 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baylor College of Medicine, which has 616 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Spironolactone is the first listed.
NCT00206232 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00206232 about?
NCT00206232 is a clinical study titled "Novel Treatment for Diastolic Heart Failure in Women". The purpose of the study is to collect information about the potential benefit and safety of low dose spironolactone for a patient with diastolic heart failure (DHF) and to determine whether spironolactone can cause the patient's condition to improve.
What is the current status of trial NCT00206232?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 48 participants. The study started on 2004-07. Estimated completion is 2010-07.
What interventions are being tested in trial NCT00206232?
The interventions under investigation include: Spironolactone (DRUG).
Who is sponsoring clinical trial NCT00206232?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.